Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV Infection

Completed · Phase 1 · Has a placebo group

Conditions studied: Chronic Hepatitis C

In brief

The purpose of this study is to investigate the safety, tolerability, and antiviral activity of ANA598 in patients with genotype-1 chronic hepatitis C infection.

Key facts

Study ID

NCT00782353

Run by

Hoffmann-La Roche

People needed

35

Starts

2008-10-01

Expected to finish

2009-03-01

Last updated by the study team

2012-11-14

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female, ages 18 to 65 years
• Documented chronic HCV infection, genotype 1a or 1b
• Treatment-naïve
• BMI = 18 - 35 kg/m2

You may not qualify if…

• Female patients who are pregnant or breast-feeding
• Previous treatment for HCV infection
• HIV or HBV positive
• Evidence of cirrhosis on previous liver biopsy or on previous imaging studies
• History of any other known cause of liver disease;

Where it is running

• United States, Missouri — St Louis, Missouri, United States
• United States, New York — New York, New York, United States
• United States, Texas — San Antonio, Texas, United States
• Puerto Rico, Santurce — Santurce, Puerto Rico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.